Bayer AG Operating Margin Growth & History (BAYN)
Bayer AG's operating margin was −2.36% for fiscal 2025.
View full Bayer AG company overviewBayer AG annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −2.36% | −2.21 pp |
| 2024 | 2024-12-31 | −0.15% | −1.44 pp |
| 2023 | 2023-12-31 | 1.28% | −12.54 pp |
| 2022 | 2022-12-31 | 13.82% | +6.21 pp |
| 2021 | 2021-12-31 | 7.61% | +26.25 pp |
| 2020 | 2020-12-31 | −18.64% | −32.12 pp |
| 2019 | 2019-12-31 | 13.48% | +3.59 pp |
| 2018 | 2018-12-31 | 9.89% | −20.81 pp |
| 2017 | 2017-12-31 | 30.70% | +15.17 pp |
| 2016 | 2016-12-31 | 15.53% | +1.87 pp |
| 2015 | 2015-12-31 | 13.66% | +0.62 pp |
| 2014 | 2014-12-31 | 13.04% | +0.75 pp |
| 2013 | 2013-12-31 | 12.29% | +2.33 pp |
| 2012 | 2012-12-31 | 9.96% | −1.40 pp |
| 2011 | 2011-12-31 | 11.36% | +5.03 pp |
| 2010 | 2010-12-31 | 6.33% | — |
Bayer AG quarterly operating margin
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 7.61% | +7.49 pp |
| Q1 2026 | 2026-03-31 | 26.32% | — |
| Q4 2025 | 2025-12-31 | 37.99% | — |
| Q3 2025 | 2025-09-30 | −5.62% | — |
| Q2 2025 | 2025-06-30 | 0.12% | — |
Bayer AG operating margin trends
Over the last five fiscal years, Bayer AG's operating margin increased from −18.64% to −2.36%, a change of +16.28 percentage points. The latest reported quarter, Q2 2026, shows 7.61%.
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
How operating margin is calculated
TickerStat calculates operating margin as reported operating income divided by reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...